Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications : A case series

Show simple item record

dc.contributor.author Lahtinen, Perttu
dc.contributor.author Mattila, Eero
dc.contributor.author Anttila, Veli-Jukka
dc.contributor.author Tillonen, Jyrki
dc.contributor.author Teittinen, Matti
dc.contributor.author Nevalainen, Pasi
dc.contributor.author Salminen, Seppo
dc.contributor.author Satokari, Reetta
dc.contributor.author Arkkila, Perttu
dc.date.accessioned 2017-11-14T14:14:07Z
dc.date.available 2017-11-14T14:14:07Z
dc.date.issued 2017-10-21
dc.identifier.citation Lahtinen , P , Mattila , E , Anttila , V-J , Tillonen , J , Teittinen , M , Nevalainen , P , Salminen , S , Satokari , R & Arkkila , P 2017 , ' Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications : A case series ' , World Journal of Gastroenterology , vol. 23 , no. 39 , pp. 7174-7184 . https://doi.org/10.3748/wjg.v23.i39.7174
dc.identifier.other PURE: 93684235
dc.identifier.other PURE UUID: 3592f4a5-be25-4ed9-96c6-bac92b99b513
dc.identifier.other WOS: 000413331400012
dc.identifier.other Scopus: 85032487896
dc.identifier.uri http://hdl.handle.net/10138/228547
dc.description.abstract Fecal microbiota transplantation (FMT) is effective in recurrent Clostridium difficile infection (rCDI). Knowledge of the safety and efficacy of FMT treatment in immune deficient patients is scarce. FMT has been suggested as a potential method for an increasing number of new indications besides rCDI. Among our FMT-treated rCDI patients, we reviewed those with major comorbidities: two human immunodeficiency virus patients, six haemodialysis patients, two kidney transplant patients, two liver transplant patients and a patient with chronic lymphatic leukaemia. We also reviewed those treated with FMT for indications other than rCDI: Salmonella carriage (two patients), trimethylaminuria (two patients), small intestinal bacterial overgrowth (SIBO; one patient), and lymphocytic colitis (one patient), as well as a common variable immunodeficiency patient with chronic norovirus infection and ESBL-producing Escherichia coli (E. coli) carriage. Of the thirteen rCDI patients treated with FMT, eleven cleared the CDI. The observed adverse events were not directly attributable to FMT. Concerning the special indications, both Salmonellas and ESBL-producing E. coli were eradicated. One trimethylaminuria patient and one SIBO-patient reported a reduction of symptoms. Three patients did not experience a benefit from FMT: chronic norovirus, lymphocytic colitis and the other fish malodour syndrome. There were no reported side effects in this group. FMT appeared to be safe and effective for immunocompromised patients with rCDI. FMT showed promise for the eradication of antibiotic-resistant bacteria, but further research is warranted. en
dc.format.extent 11
dc.language.iso eng
dc.relation.ispartof World Journal of Gastroenterology
dc.rights cc_by_nc
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject Faecal microbiota transplantation
dc.subject Antibiotic resistance
dc.subject Clostridium difficile infection
dc.subject Microbiota
dc.subject Immunodeficiency
dc.subject Salmonella infection
dc.subject ACTIVE ULCERATIVE-COLITIS
dc.subject CONTROLLED-TRIAL
dc.subject INFECTION
dc.subject RECURRENT
dc.subject CARRIAGE
dc.subject DISEASE
dc.subject EFFICACY
dc.subject THERAPY
dc.subject UPDATE
dc.subject GENES
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications : A case series en
dc.type Article
dc.contributor.organization HYKS erva
dc.contributor.organization Department of Medicine
dc.contributor.organization Infektiosairauksien yksikkö
dc.contributor.organization Clinicum
dc.contributor.organization Research Programs Unit
dc.contributor.organization Reetta Maria Satokari / Principal Investigator
dc.contributor.organization Immunobiology Research Program
dc.contributor.organization University of Helsinki
dc.contributor.organization Gastroenterologian yksikkö
dc.contributor.organization HUS Inflammation Center
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization HUS Internal Medicine and Rehabilitation
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.3748/wjg.v23.i39.7174
dc.relation.issn 1007-9327
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
WJG_23_7174.pdf 8.020Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record